https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/accelerated-approval-request-new-drug-rare-childhood-muscle-disorder/
Accelerated approval request for a new drug for a rare childhood muscle disorder
9 Sep 2015, 4:41 p.m.
A drug for Duchenne Muscular Dystrophy (DMD), originally developed by BRC Theme Lead Professor Francesco Muntoni’s Consortium in the UK, has been filed by Sarepta Therapeutics for accelerated approval by the United States Food and Drug Adminstration (FDA).The drug Eteplirsen is an antisense oligonucleotide that is designed to enable the production of a functional truncated dystrophin protein to alleviate some of the symptoms of DMD.
DMD is an X-linked rare degenerative neuromuscular disorder that causes severe progressive muscle loss and premature death. It is one of the most common fatal genetic disorders, affecting approximately one in every 3,500 boys born worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fibre function. The condition is universally fatal, and death usually occurs before the age of 30.
The findings from the original study were reported in the Lancet in 2011. The first patient to receive the systemic injection of this novel compound was performed in the BRC-supported Somers Clinical Research Facility at GOSH.
New Director Designate announced for NIHR GOSH Biomedical Research Centre
Professor Paul Gissen has been announced as the Director Designate of the NIHR GOSH Biomedical Research Centre.
Study linking data from 85% of children in England compares rare cardiac risks post-COVID vs vaccination
A major study which analysed anonymised health records from over 14 million children in England has shown that rare heart and inflammatory issues were more likely - and lasted longer - after COVID-19 infection than after vaccination.
Celebrating research that transforms lives
The 2025 NIHR GOSH BRC Showcase recently celebrated some incredible progress made in paediatric research.
Landmark gene therapy study shows safety for children
Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment.